clinical trial · NCT05403827
A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease
Kowa Research Institute, Inc.·phase3·completed·n = 644
Dry Eye DiseaseK-161Placebo
brief summary
The purpose of this study is to assess the efficacy and safety of K-161 ophthalmic solution for the treatment of moderate to severe dry eye disease.
started
Jul 3, 2022
primary completion
Aug 25, 2023
completion
Dec 5, 2023
last updated
Jan 14, 2025
official title
A Phase 3, Prospective, Double-masked, Randomized, Multi-center, Vehicle-controlled, Parallel-group, 12-week Administration and 40-week Extension Study Confirming the Efficacy and Safety of K-161 Ophthalmic Solution for the Treatment of Moderate to Severe Dry Eye Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol